So is the $13.25 PT based solely on success with aGVHD? That suggests about $3.50 on ASX - that would be good start just for aGVHD. The commercial value of their other treatments will be far greater than the US$100M indicated for aGVHD - in would be interesting to see a PT based on any one of those. I'll go out on a limb and put a PT of AU$13.50 if they can add another product success on top of aGVHD. Just an opinion, DYOR.
Cell Therapy News/Articles, page-117
-
- There are more pages in this discussion • 17,709 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.105(8.37%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.23 | $1.14 | $9.583M | 8.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |